CIPLA

Cipla is expanding strongly in the US generics and respiratory drug markets. Q1 FY26 revenue grew 12% YoY, aided by strong sales in inhalers. Domestic formulations remain stable with steady growth in chronic therapies. Margins at 23% highlight efficiency in operations. The company is also focusing on biosimilars for long-term growth. Valuations at ~24x FY26 EPS are attractive compared to Sun Pharma. Cipla offers a mix of defensive stability and growth potential, making it suitable for balanced portfolios.